# Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

> **NCT00255658** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** temsirolimus
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00255658
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00255658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00255658, "Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00255658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*